

Item 7.01 Regulation FD Disclosure.

On May 15, 2017, Cellular Biomedicine Group, Inc. issued a press release announcing the addition of a second clinical site in the expansion of its Chimeric Antigen Receptor T-Cell (CAR-T) Phase I clinical trial for its ongoing CAR-T studies in patients with Non-Hodgkin Lymphoma. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release, dated May 15, 2017

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cellular Biomedicine Group,
Inc.

Date: May 15, 2017 By: /s/ Bizuo (Tony) Liu
Bizuo (Tony) Liu
Chief Executive Officer